We investigated the relationships between body mass index change (DBMI) and prognoses and clinical effects of patients with advanced colorectal cancer (CRC).
Introduction
Colorectal cancer (CRC) is a very common malignant tumor with high recurrence rates and poor prognoses. [1] CRC accounts for about 8% of all newly diagnosed cancers and 8% to 9% of all new cancer-related mortalities. [2] Mortalities from CRC have greatly decreases, possibly because of new technologies that enable earlier diagnoses and better treatments. [3, 4] However, the long-term survival rate is relatively low for patients with CRC, [1] wherein the 5-year relative survival rate ranges from >90% in patients with stage I CRC to slightly >10% in patients with stage IV of CRC. [5] In China, CRC ranks fifth in overall number of cancer deaths, and the CRC incidences are continually on the rise, [3] especially for patients with advanced, late stage. It has been reported that in 15% to 25% of patients with CRC, metastasis occurs before diagnosis. This has become the key obstacle in the effective treatment of colon cancer.
Accordingly, it is necessary to identify predictors related to CRC progression and invasion, which may help patients select the appropriate treatment and monitoring. [1] Body mass index (BMI), which is defined as the relation of one's weight in kilograms divided by the square of one's height in meters, is a useful tool in clinical practice for assessing adult weight and nutritional status. Higher BMIs are related to morbidity and prognoses [6, 7] and can increase surgical complications, such as incision infections and laparoscopic operation difficulties. [8, 9] A reverse association between weight change and cancer risk has been observed in locally advanced pancreatic cancer, [10] breast cancer, [11] [12] [13] gastric cancer, [14] CRC, [15] non-small cell lung cancer [16] , and endometrial cancer. [17] Innominato et al [18] reported that weight loss during chemotherapy had a close relationship with poor overall survival (OS). However, few studies have investigated the associations between BMI change
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(DBMI) during chemotherapy, clinical effects, and CRC prognosis. Therefore, we performed a retrospective cohort study to assess the relation of these factors to DBMI.
Materials and methods

Study population
From January 2008 to December 2012, a total of 224 patients with stage IV CRC were treated at our hospital and were included in this retrospective study. Among these patients, 132 (58.9%) were men, 92 (41.1%) were women, and the median age was (63.2 ± 12.2) years. Patients were diagnosed with colonoscopy in combination with histopathological examinations. Clinical pathological and survival data were collected. The factors of age, sex, type of pathology, differentiation, site of tumor and metastasis, lymph node metastasis, and survival were included in this study. This study was approved by the Ethics Committee of our hospital. All patients or their relatives gave informed consent.
Inclusion and exclusion criteria
Inclusion criteria were: complete clinicopathologic materials, pathologically established diagnosis pathologically, no previous radical resection, eastern cooperative oncology group performance status (ECOG PS) scores 2, distant metastases confirmed by image examinations, such as positron emission tomographycomputed tomography (PET-CT), ECT, CT, and magnetic resonance imaging (MRI), undiagnosed multiple diseases, including coronary heart disease, cerebral infarction, diabetes mellitus, among others, completion of at least 2 cycles of XELOX or folinic acid (leucovorin)-fluorouracil-oxaliplatin (FOLFOX) regimens.
Exclusion criteria were: incomplete clinicopathologic materials, patients with stage I-III CRC, simple, localized liver or lung metastasis which were radically resected, relapse after radical resection, neoadjuvant chemotherapy, unwillingness to give informed consent or undergo follow-up.
How to calculate DBMI
Height and weight outcomes before chemotherapy and after 2 cycles of chemotherapy were collected. BMIs were calculated before and after 2 cycles of chemotherapy, based on BMI (weight [kg]/height squared [m 2 ]). DBMI during chemotherapy was calculated as BMI (after 2 cycles of chemotherapy)-BMI (before chemotherapy).
Treatment
Patients were only treated with chemotherapy. The standard chemotherapy included the CapeOX scheme, which is a 3-hour intravenous infusion of oxaliplatin (130 mg/m 2 ) on day 1, and on days 1 to 14, oral capecitabine (1000 mg/m 2 ) was administered 2 times a day. Every 3 weeks, a total of 8 cycles were completed. The FOLFOX scheme included leucovorin (200 mg/m 2 ), given as a 2-hour infusion, and oxaliplatin (85 mg/ m 2 ) as a 2-hour infusion, followed by a bolus infusion of 5-FU (400 mg/m 2 ) and a continuous infusion of 5-FU (2400 mg/m 2 ) for 46 hours. This regimen was repeated every 2 weeks for 12 cycles. [19] The bevacizumab dose was 7.5 mg/kg, and it was administered every 2 weeks, initially over 90 minutes. If the first infusion was well tolerated, the second was delivered over 60 minutes, and if the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes. Cetuximab was administered weekly (at an initial dose of 400 mg/m 2 , intravenously over 120 minutes, and subsequently at 250 mg/ m 2 over 60 minutes on day 1 of each cycle (CRC whose tumors do not harbor a KRAS mutation). Clinical effects were evaluated by imaging studies, after 2 cycles of chemotherapy.
Clinical effect
The Response Evaluation Criteria in Solid Tumors (RECIST) was proposed as a standard evaluation, the content of which was as follows: complete response (CR), partial response (PR), stable disease (SD),(progressive disease (PD).The disease control rate (DCR) was equal to (CR + PR + SD). The clinical efficacy was evaluated after two cycles of chemotherapy, and if disease progression was suspected, the evaluation was performed ahead of time.
Follow up
Follow-up studies were performed as follows: once every month for the first year, once every 3 months for years 2 to 3, and once every 6 months after year 3. The last follow-up date was December 1, 2015.The follow-up periods ranged from 3 to 78 months (median: 25 months). Progression-free survival (PFS) time was defined as the duration between pathological diagnosis and the development of local recurrence or distant metastases. OS time was defined as the duration between the date of pathological diagnosis to the date of death or final follow-up of deceased and surviving patients, respectively.
Statistical analysis
All statistical analyses were performed with the SPSS 20.0 (SPSS Inc, Chicago, IL). The Spearman rank correlation analysis was used to analyze DBMIs and clinical effects. Independent sample t tests were used to examine differences of normally distributed data.
The receiver-operating characteristics (ROC) curve identified À0.45 as the optimal cutoff value for DBMI, in terms of OS and PFS. Patients were then divided into DBMI high (DBMI≥ À0.45 kg/m 2 ) and DBMI low (DBMI À0.45 kg/m 2 ) groups, according to the optimal cut-off. [20] The Spearman rank Pearson correlation tests were used to identify correlations among clinicopathological parameters and DBMI. Survival curves were constructed, and the Kaplan-Meier method was used to analyze OS and PFS in patients with CRC. Survival differences were analyzed by the logrank test, which was used to compare the survival distributions of the variables. Noncategorical variables were transformed into 2 categorical variables, according to their respective mean values. The Cox proportional hazards model was used to analyze the influence of variables on OS time. All reported P values were 2-tailed, and those <.05 were considered statistically significant.
Results
No significant relationships were identified between prediagnosis BMI, DBMI, and clinical effect
A total of 114 patients (50.9%) was in the high DBMI group and 110 (49.1%) were in the low DBMI group. Correlations between DBMI and clinical effects were studied by the Spearman rank Cong et 
Significant correlation was found between DBMI and carcinoembryonic antigen
There were no significant differences between the high DBMI group and the low DBMI group in terms of sex, age, chemotherapy, ECOG PS, operation history, tumor differentiation, and lymph nodes metastasis (P = .82, .126,.90, .066, .781, .220, and .788,respectively). However, there were significant differences in histology (P = .04) and DBMI between the high DBMI and low DBMI groups (P < .001) ( Table 1 ). The Pearson correlation test showed that DBMI and carcinoembryonicantigen (CEA) had a mild negative correlation, with a significant difference (R = À0.228, P = .001). The Spearman rank correlation results showed that DBMI and operation history also had a mild negative correlation, with a significant difference(R = À 0.179, P = .007).
Comparison between the high DBMI and low DBMI group survival rates
The independent sample t test results showed that there were no significant differences between the median PFS values of the high DBMI and low DBMI groups (P = .530) (Fig. 1) . The median OS durations of the 2 groups were 27.0 ± 0.40 and 28.0 ± 0.29 months, respectively. The OS of the high DBMI group was significantly higher than that of the low DBMI group (Fig. 2 , P = .002).
DBMI was an independent prognostic determinant of OS in patients with CRC
The log-rank showed that there were no significant differences in sex (P = .644), distant metastasis (P = .879), tumor differentiation (P = .134), diseases location (P = .898), chemotherapy (P = .553), lymph nodes metastasis (P = .925), T stage (P = .644), histology (P = .86), and the survival rates of patients with CRC. However, there were significant differences in CEA (P < .001), family history (P = .008), DBMI (P < .001), ECOG PS (P < .001), age at diagnosis (P < .001), operation history (P = .011), prechemotherapy BMI (P < .001), and OS. The cox regression analysis confirmed that family history (P = .041), ECOG PS (P = .001), DBMI (P = .023), and CEA (P = .02) were independent factors in the prediction of OS rates in patients with CRC. The above data indicate that decreased DBMI can predict OS rates in patients with CRC. Operation history Table 1 The basic clinicopathological parameters of 224 CRC patients. (P = .10), tumor differentiation (P = .23), and prochemotherapy BMI (P = .42) cannot predict OS rates in patients with CRC ( Table 2 ).
Discussion
Worldwide, CRC is the second most commonly diagnosed cancer in women and the third in men. There have been an estimated 1,360,000 new cases of CRC, and nearly 700,000 deaths, in 2012. [21] [22] [23] Numerous previous studies have shown that BMI not only relates to CRC morbidity, but also mortality. [24] Prediagnostic BMI has been associated with survival of patients with CRC and follows a U-shape pattern. Both obesity [25] [26] [27] (BMI ≥30 kg/m 2 ) and underweight (BMI <18.5 kg/m 2 ) [28] are associated with high mortality [29] and are strong risk factors for the long-term prognosis of patients with CRC. Furthermore, Laake et al [27] also found that weight gain was associated with higher CRC-specific mortality in women with CRC. However, these results are controversial. Junzhong et al [30] reported that weight loss during preoperative chemoradio therapy was an independent prognostic factor for OS. Other research has shown that severe weight loss directly contributes to up to one-fifth of cancer deaths and has a significant effect on patient quality of life. [31] Hoffmeister et al [32] suggested that overweight and obesity maybe associated with increased risk, in female patients with microsatellite-instable-high CRC. Croft et al doubted whether BMI could be used to measure the value of obesity in the prognosis of local CRC. [33] However, in a recent study, Shiao et al [34] reported that BMI is a predictor of CRC. Whether BMI changes influence the survival of patients with CRC has been unclear.
In this study, there were no significant differences between prediagnosis BMI, DBMI, and clinical effects. These results indicate that prediagnosis BMI and DBMI could not predicate clinical effects or provide reliable references for making or changing chemotherapy decisions. Furthermore, other studies have reported similar results. [35] In our study, there were significant differences between DBMI and histology and CEA. There were no significant differences between DBMI and sex, chemotherapy, ECOG PS, operation history, tumor differentiation, age of diagnosis, and lymph node metastases. Innominato et al [18] reported that weight loss during chemotherapy was closely related to poor prognosis. Daniel et al [36] observed that weight change did not correlate with PFS, which is in agreement with our results; however, Lee et al [37] found that weight gain during therapy was associated with unfavorable survivor rates. These results differ from ours, and in our study, DBMI could be used to predict OS rates in patients with CRC. This difference could be attributed to the enrollment of patients with stage II-III CRC. Most patients with early-stage CRC need operative treatment, and patients with a high DBMI, especially those who are obese, should undergo operations with caution because of their increased postoperative morbidity risk. [25, 38] High DBMI might cause metabolic abnormalities, low immunogenicities, and intestinal inflammation, which leads to poor prognoses of patients with CRC. Advanced stages of cancer are often accompanied by malnutrition, and such patients cannot tolerate operations. Therefore, high DBMI provides as a marker for nutritional assessments [39] that can be utilized to improve poor nutritional statuses, which could ultimately enhance chemotherapy tolerance. Therefore, DBMI has a direct connection with favorable prognosis.
CEA, family history, DBMI, ECOG PS, tumor differentiation, operation history, and prochemotherapy BMI were significant risk factors for OS. The results of the cox analysis confirmed that family history, ECOG PS, DBMI, and CEA were independent predictors of OS rates in patients with CRC. The above results indicate that downregulated DBMI is predictive of poor prognoses in patients with CRC. Operation history, tumor differentiation, and prochemotherapy BMI were not independent predictors of OS. The relative risk is 0.72-fold for patients with CRC with high DBMI levels, compared to those with those with lower DBMI levels. DBMI is predictive factor of CRC survival rates.
In our study, patients with stage IV CRC who could not accept operations were enrolled. Lower DBMI levels often suggest poor nutritional statuses, which might compromise prognoses of patients with types of cancers, before and during anti-tumor treatments. [30] DBMI decreases owing to cachexia is a common symptom for patients with advanced cancer, [40] and decreased DBMI is also a risk factor for CRC-specific mortality. [34] However, because of our small sample size and inclusion of patients with higher TNM stages, we should further study DBMI levels across larger patient cohorts. Lee et al [37] reported that weight gain was a poor prognosis factor, especially for patients who are overweight or obese. The prognostic differences might also be associated with different TNM stages and treatments.
Conclusions
We demonstrated that DBMI decrease predicts a poor prognosis for patients with advanced CRC, and high DBMI is a predictive factor for survival. DBMI is an independent predictive factor of CRC survival rates. 
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